Cardio-Metabolic Drug Targets  

 

ABOUT THIS CONFERENCE 

Cardiovascular disease, diabetes, obesity and dyslipidemia, though traditionally treated as separate entities, are often conditions that appear together in individuals because of defects in underlying metabolic processes. Researchers are therefore now seeking compounds that target biological points of intersection of these related diseases in the hopes of 'killing more birds with one stone.' Or they are approaching drug development of a compound for a specific disease with a greater awareness of the backdrop of related conditions.

Join fellow biomedical researchers from academia and industry at our day and a half conference, Cardio-Metabolic Drug Targets to discuss the impact of this paradigm change in the way drugs are discovered and developed in the cardio-metabolic arena and to stay abreast of the latest targets and drug development candidates in the pipeline.

SUGGESTED EVENT PACKAGE: 

 

September 23: Allosteric Modulators of GPCRs Short Course 4  

September 24 - 25: Novel Strategies for Kinase Inhibitors Conference  

September 25: Setting Up Effective Functional Screens Using 3D Cell Cultures Dinner Short Course  

September 25 - 26: Cardio-Metabolic Drug Targets Conference 


Scientific Advisory Board:

Jerome J. Schentag, Pharm.D., Professor of Pharmaceutical Sciences, University at Buffalo

Rebecca Taub, M.D., Ph.D., CEO, Madrigal Pharmaceuticals

 

Day 1 | Day 2 | Download Brochure | Download Track Brochure 

  

Wednesday, September 25

11:50 am Registration


1:30 pm Chairperson’s Opening Remarks

 

1:40 Plenary Keynote Speakers

Stuart L. Schreiber
Towards a Patient-Based Drug Discovery  
 

Stuart L. Schreiber, Ph.D., Director, Chemical Biology, Founding Member, Broad Institute of Harvard and MIT; Howard Hughes Medical Institute Investigator; Morris Loeb Professor of Chemistry and Chemical Biology, Harvard University

 Paul L. Feldman
Enteroendocrine Drug Discovery for Treatment of Metabolic Diseases
 

Paul L. Feldman, Ph.D., Senior Vice President, GlaxoSmithKline

 

(also panelist in 'Cardio-Metabolic' track, day 2, 2:30pm 'Challenges in Diabetes and Atherosclerosis Drug Development') 

For complete Keynote details, click here 

 

3:10 Refreshment Break in the Exhibit Hall with Poster Viewing


BEYOND STATINS: NEW APPROACHES FOR REGULATING LIPID METABOLISM AND ATHEROSCLEROSIS 

3:50 pm Chairperson’s Opening Remarks
Rebecca Taub, M.D., Ph.D., CEO, Madrigal Pharmaceuticals 

4:00 FEATURED SPEAKER: Atherosclerosis and Cardio-Metabolism Research Overview: Promising Targets

Margrit SchwarzMargrit Schwarz, Ph.D., MBA, President, MS Consulting, LLC; formerly Director of Research, Dyslipidemia and Atherosclerosis, Amgen

Dyslipidemia as a risk factor for cardiovascular disease (CVD) is being effectively treated with statins, though residual CVD risk in most patients has prompted the development of new therapies. PCSK9 inhibitors have emerged as a new class of LDL-C lowering drugs with promising efficacy in clinical trials. Will they effectively address residual CVD risk, or is there a need for additional therapies that target atherosclerosis more directly? Drug discovery strategies beyond PCSK9 are being discussed.

Global Genomics Group4:30 Combining Next-Generation Phenotyping with Panomics – A New Standard for Biomarker and Drug Discovery

Szilard Voros, M.D., Founder & CEO, Global Genomics Group LLC

We present a comprehensive and integrated approach for biomarker and target discovery that addresses the shortcomings of current approaches to investigate disease-relevant pathways. By combining next-generation phenotyping through the use of advanced imaging with panomics, we investigate and analyze comprehensive, multidimensional biological networks. Our current focus is atherosclerosis in cardiovascular diseases.

5:00 Novel Treatment for Dyslipidemia: Liver-Directed Thyroid Hormone Receptor-ß Agonist

Rebecca TaubRebecca Taub, M.D., Ph.D., CEO, Madrigal Pharmaceuticals

Insulin resistant type 2 diabetics have a high incidence of atherosclerosis, and 65-80% of diabetics die of cardiovascular (CV) disease such as heart attacks and strokes.  Diabetes is associated with a dyslipidemia characterized by fatty liver, elevated triglycerides
(TGs), atherogenic LDL particles and low HDL cholesterol. MGL-3196, a liver-targeted THR beta agonist has a unique profile including insulin sensitization, reduction of cholesterol, triglycerides and liver triglycerides in animal models and reduction in LDL cholesterol (30%), triglycerides (60%) in human studies. MGL-3196 may be highly effective treatment for diabetic dyslipidemia that can reduce CV risk in type-2-diabetics.

5:30 Modulating Glycerolipid Metabolism in Myeloid Cells for Cardiometabolic Benefit

Suneil K. Koliwad, MD., Ph.D. Assistant Professor, Diabetes Center/Department of Medicine, University of California San Francisco (UCSF)

Intestinal DGAT enzymes have been targeted to lower body weight and reduce the progression of metabolic syndrome. Unfortunately, DGAT inhibition is associated thus far with several unwanted side effects. We have used these targets to uncover a link between glycerolipid flux within myeloid cell types (macrophages, dendritic cells, microglia) and inflammatory responsiveness. The work from our group has focused on DGAT enzymes as tools to modulate the flux of fatty acids within innate immune cells that are activated in metabolic tissues in the face of diet-induced obesity.

6:00  Targeting PCSK9 for Hypercholesterolemia and Atherosclerosis

Hong Liang, Ph.D., Associate Research Fellow, Rinat Research Unit, Pfizer

PCSK9 promotes LDLR degradation and increases serum LDL-C. We show that a humanized mAb (J16) potently and selectively reduces LDL-C in cynomolgus monkeys and humans. This effect is additive to that of the HMG-CoA reductase inhibitor. Furthermore, we show that a Mab engineered to have pH-sensitive binding to PCSK9 (J17) minimizes PCSK9-mediated degradation leading to extension in antibody half-life and prolonged duration of efficacy.

6:30 Close of Day


Day 1 | Day 2 | Download Brochure | Download Track Brochure   

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag 


2014 Discovery on Target Brochure  

green arrow FINAL BROCHURE 

PREMIER SPONSORS 

Cellecta 

green arrow VIEW ALL SPONSORS 

green arrow VIEW MEDIA PARTNERS 


SPONSORSHIPS & EXHIBITS 

The exhibit hall was sold out in 2013, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2014, contact:

Jon Stroup
Business Development Manager
781-972-5483
jstroup@healthtech.com 

2014 Discovery On Target CAG 

green arrow CONFERENCE-AT-A-GLANCE 


CONFERENCES


October 8 – 9

Targeting Epigenetic Readers and
Chromatin Remodelers
 

Targeting the Ubiquitin Proteasome System  

Big Data Analytics and Solutions  

GPCR-Based Drug Discovery  

RNAi for Functional Genomics Screening
– Part 1
 

Protein-Protein Interactions as Drug Targets  

Antibodies Against Membrane Protein Targets
– Part 1
 


October 9 – 10

Targeting Histone Methyltransferases and Demethylases  

Screening Drug Transporter Proteins  

Maximizing Efficiency in Discovery  

GPCR-Targeted Therapeutics  

Genome Editing for Functional Genomics
Screens – Part 2
 

Cancer Metabolism  

Antibodies Against Membrane Protein Targets
– Part 2
 


SYMPOSIUM


October 7

Next Generation Histone Deacetylase Inhibitors  


SHORT COURSES


October 7

SC1: Designing Scalable Software Systems for Big Data Analytics  

SC2: Approaches for Biologically-Relevant Chemical Diversity  

SC3: Setting Up Effective RNAi Screens: From Design to Data to Validation  

SC4: Targeting Protein-Protein Interactions  

SC5: GPCR Structure-Based Drug Discovery  

SC6: Advances in Metagenomic Drug Discovery for New Anti-Infective Agents  

SC7: Targeting of GPCRs with Monoclonal Antibodies  

SC8: A Primer to Gene Editing: Tools and Applications  

SC9: Introduction to Targeted Covalent Inhibitors  


October 9

SC10: Setting Up Effective Functional Screens Using 3D Cell Cultures  

SC11: Integration of BDDCS and Extended Clearance Principles  

SC12: Introduction to Allosteric Modulators and Biased Ligands of GPCRs  

SC13: Introduction to Drug Metabolism